Intratympanic steroid injection as a first-line therapy in uremia patients with sudden sensorineural hearing loss. (August 2015)

• Record Type: Journal Article
• Authors: Tsai, Hsun-Tien; Hsueh, Naiwei; Huang, Chih-Ming; Lin, Hung-Ching
• Is Part Of: Acta oto-laryngologica. Volume 135:Number 8(2015)
• Page Start: 786
• Page End: 790
• Publication Date: 2015-08
• Subjects: Otolaryngology -- Periodicals; Ear -- Diseases -- Periodicals; Throat -- Diseases -- Periodicals; Otolaryngology -- Electronic Resources; Otorhinolaryngologic Diseases; 617.8
• DOI: 10.3109/00016489.2015.1027413
• Languages: English
• ISSNs: 0001-6489

Abstract

<abstract> <title>Abstract</title> <p> <italic>Conclusions:</italic> ITSI as a first-line therapy in uremia patients with SSNHL offers a valid and safe treatment compared with intravenous systemic steroid treatment. A specific pathophysiology caused by possible sodium pump paralysis may be explained for uremia patients with SSNHL. <italic>Objective:</italic> To compare the efficacy of intratympanic steroid injection (ITSI) with that of systemic intravenous steroids as a first-line therapy in uremia patients with sudden sensorineural hearing loss (SSNHL). <italic>Materials and methods:</italic> A total of 23 consecutive uremia patients with SSNHL were enrolled in this study. Patients were divided into two groups: the ITSI group (<italic>n</italic> = 15) and the non-ITSI group (<italic>n</italic> = 8), in which patients received intravenous systemic steroid treatment. The two groups were homogeneous in all respects. <italic>Results:</italic> The hearing improvement and relative gain were statistically significant between the two groups. The value of hearing gain (ΔPTA = PTA _pre – PTA _post) in the ITSI group and the non-ITSI group was 24.6 ± 16.4dB and 8.4 ± 19.3dB. The value of relative gain (ΔPTA/PTA_pre) in the ITIS group and the non-ITSI group was 31.1 ± 22% and 9.4 ± 20.5%. In the ITSI group, 11 patients (73.3%) exhibited hearing recovery (ΔPTA &gt; 10 dB).</p> </abstract>